II. Indications
III. Mechanism
- CD30
- CD30 is a Tumor Necrosis Factor (TNF) receptor found on the surface of White Blood Cells
- CD30 is overexpressed in hematopoietic malignancies
- CD30 Monoclonal Antibody
- Conjugate antibodies that deliver cytotoxic drugs to CD30 positive cancer cells
IV. Medications
- Brentuximab vedotin (Adcetris)
- Conjugated Monoclonal Antibody that delivers the cytotoxic drug monomethyl auristatin E (MMAE) to cancer cells
- Used in Hodgkins Lymphoma
V. Dosing
- See other references for disease specific dosing protocols
VI. Adverse Effects
- Peripheral Neuropathy
- Infusion reactions (including Anaphylaxis)
- Cytopenia
-
Immunosuppression
- Risk of opportunistic infections
- Hepatotoxicity
- Tumor Lysis Syndrome
- Pulmonary toxicity
- Severe dermatologic conditions
- Other common adverse effects
- Hyperglycemia
- Gastrointestinal effects (Nausea, Vomiting, Diarrhea, Constipation, Abdominal Pain, weight loss)
- Stomatitis and mucositis
- Alopecia
VII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters, Unknown Pregnancy category)
- Use reliable Contraception
- Monitoring
- Complete Blood Count
- Liver Function Tests (including Serum Bilirubin)
VIII. Drug Interactions
-
Bleomycin
- Avoid in combination with Brentuximab (risk of pulmonary toxicity)